MARKETS
Markets

Sarepta Therapeutics Appoints Michael Severino CEO, Effective July 28, Succeeding Doug Ingram

Jul 27, 2026 · 08:37 AM ET· updated 3h ago

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Michael Severino, M.D., as chief executive officer, effective July 28, 2026.

Share
Why It Matters

Sarepta is getting a new leader starting July 28—Michael Severino will be the boss instead of Doug Ingram. When a company changes its top leader, watch how the company does over the next year to see if the new person's ideas work well.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.